A Prospective, International, Longitudinal, Observational Disease Registry of Patient-reported Outcomes (PROs) and the Association With Hemophilia A and Its Treatment in Patients With Moderate to Severe Hemophilia A
Phase of Trial: Phase IV
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms ECHO
- Sponsors Bayer
- 10 Jun 2017 Biomarkers information updated
- 19 Feb 2017 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2020.
- 12 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.